ALS and Riluzole: How This Drug Slows Neurodegeneration

When a doctor says you have Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's Disease or a progressive neurodegenerative disorder affecting upper and lower motor neurons, the words that follow are usually heavy. It is a condition where the nerves controlling your muscles slowly die off. The result is weakness, paralysis, and eventually, difficulty breathing. For decades, there was no drug to stop it. Then came Riluzole, the first FDA-approved medication for ALS, developed by Rhône-Poulenc Rorer (now Sanofi).

Riluzole isn't a cure. It won't make the muscle strength come back. But it does something important: it buys time. Since its approval in 1995, it has been the standard of care for people with ALS. In this guide, we break down how riluzole works, what the survival benefits really mean, and why it remains a critical part of ALS management even as new drugs enter the market.

Understanding ALS and the Need for Treatment

To understand why riluzole matters, you first need to grasp what ALS is doing to the body. ALS targets two types of motor neurons: the upper ones in your brain and the lower ones in your spinal cord. When these cells die, the signal telling your muscles to move stops getting through. You start with small twitches or weakness in a hand or foot. Over time, that spreads. Speech becomes slurred. Swallowing gets hard. Breathing requires assistance.

The timeline is harsh. Without intervention, most people live three to five years after symptoms start. That is the baseline. Any treatment that pushes that line out, even slightly, is considered a victory in the world of neurology. Before 1995, doctors could only offer supportive care-breathing machines, feeding tubes, physical therapy. There was no pill to change the course of the disease. Riluzole changed that narrative completely.

How Riluzole Works: Blocking Glutamate Toxicity

You might wonder how a small pill can slow down such a complex disease. The answer lies in chemistry, specifically in a neurotransmitter called glutamate. Think of glutamate as the brain’s main "on" switch. It helps neurons talk to each other. But in ALS, there is too much glutamate hanging around. This excess causes excitotoxicity. Imagine shouting at someone until their ears bleed; that’s essentially what high glutamate levels do to motor neurons. They get overstimulated and die.

Riluzole acts as a glutamate antagonist that reduces excitotoxicity by inhibiting glutamate release and blocking sodium channels. It doesn’t just block the receptor; it tackles the problem from multiple angles:

• Inhibits Release: It stops nerve endings from dumping too much glutamate into the space between neurons.
• Blocks Sodium Channels: By inactivating voltage-dependent sodium channels, it calms the electrical firing of neurons.
• Antagonizes Receptors: It interferes with NMDA and AMPA receptors, preventing glutamate from binding and causing damage.

While the exact mechanism is still debated among researchers, the consensus is clear: riluzole reduces the toxic stress on motor neurons, allowing them to survive longer than they would otherwise.

Survival Benefits: What the Data Actually Shows

Let’s talk numbers, because this is where patients and families often feel confused. Clinical trials show that riluzole extends median survival by about two to three months compared to placebo. Some real-world studies suggest the benefit might be larger-up to six to nineteen months in some cases-but the landmark data points to that modest 2-3 month window.

Does two months matter? In the context of a fatal disease with no cure, yes. It means more time with family, more time to settle affairs, or simply more days of independence. A major study published in The Lancet involving nearly 1,000 patients showed a 35% reduction in the risk of death or needing a tracheostomy at 18 months for those taking the standard 100mg dose. That is a statistically significant improvement in quality of life and longevity.

Dosing, Forms, and Side Effects

Riluzole comes in several forms now, which makes it easier for people who struggle to swallow-a common symptom in later stages of ALS. Originally, it was only available as a 50mg tablet (Rilutek, brand name for riluzole tablets manufactured by Sanofi). Today, you can also get an oral suspension (Tiglutik, oral suspension formulation of riluzole approved in 2018) or an oral thin film (Exservan, dissolvable film formulation of riluzole approved in 2020). The film dissolves on the tongue, which is a huge help for patients with dysphagia.

The standard dose is 100mg per day, split into two 50mg doses taken twice daily. It takes about a week to build up tolerance. Doctors usually start patients on 50mg once a day for seven days before moving to the full dose.

Side effects are real, but manageable for most. About one in four patients experience nausea. Fatigue is also common, reported by 20% of users. The biggest concern is liver toxicity. Riluzole can raise liver enzymes, so doctors require blood tests before starting the drug and monthly for the first three months. If your liver enzymes spike too high, you may need to stop the medication. Only about 8% of patients quit due to intolerable side effects, meaning the vast majority stay on the drug because the benefits outweigh the discomfort.

Real-World Experience vs. Clinical Trials

Clinical trials are controlled environments. Real life is messy. Some studies show riluzole working better in practice than in labs, possibly because trial participants are often sicker or older than the general ALS population. Others show no benefit at all. Why the difference?

It likely comes down to individual biology. ALS is not one single disease; it’s a spectrum. Some people progress quickly, others slowly. Riluzole seems to work best in certain subgroups, though we don’t yet know exactly which ones. Patient forums reflect this variability. Many users report that while the nausea was tough initially, they felt their progression slowed. Others feel frustrated when liver issues force them off the drug. Despite this, 63% of patients remain on riluzole after one year, suggesting that most find value in continuing treatment.

The Future of ALS Therapy

Riluzole is no longer the only game in town. Edaravone, approved in 2017, offers another option, particularly for early-stage patients. More recently, tofersen (Qalsody) was approved in 2023 for a specific genetic form of ALS caused by SOD1 mutations. These advances are exciting, but they don’t replace riluzole. Instead, they complement it. Experts predict that combination therapies-using riluzole alongside newer drugs-will become the norm. For now, if you have ALS, riluzole remains the foundational treatment. It’s not perfect, but it’s proven.